Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
brain cancer
Biotech
Imvax takes brain cancer therapy to FDA despite missing primary
Imvax shrugged off the failure to hit its primary endpoint, reporting evidence of improved overall survival and making a beeline for the FDA.
Nick Paul Taylor
Dec 2, 2025 8:00am
NCI axes funding for pediatric brain cancer trial consortium
Aug 26, 2025 6:50am
Alpheus nets $52M for ultrasound-activated brain tumor therapy
May 16, 2025 12:26pm
Telix shows 'promising’ 13-month OS in ph. 2 brain cancer study
Apr 16, 2025 6:30am
Jazz hands Chimerix $935M to buy near-approval cancer drug
Mar 5, 2025 8:13am
Merck snaps up preclinical DNA biotech for $1.3B biobucks
Oct 23, 2024 7:05am
